Santhera Pharmaceuticals (OTCMKTS:SPHDF) Trading Up 12.2% – Still a Buy?

Santhera Pharmaceuticals Holding AG (OTCMKTS:SPHDF)’s stock price was up 12.2% during trading on Thursday . The company traded as high as $22.00 and last traded at $22.00. Approximately 1,800 shares changed hands during mid-day trading, an increase of 19% from the average daily volume of 1,509 shares. The stock had previously closed at $19.60.

Santhera Pharmaceuticals Price Performance

The stock’s 50-day moving average is $19.73 and its 200 day moving average is $15.61.

Santhera Pharmaceuticals Company Profile

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative therapies for rare neuromuscular and pulmonary diseases. Headquartered in Pratteln, Switzerland, the company concentrates on addressing high unmet medical needs in conditions such as Duchenne muscular dystrophy (DMD), limb‐girdle muscular dystrophies and other mitochondrial or neuromuscular disorders. Santhera’s corporate strategy emphasizes both in‐house development and strategic partnerships to advance its drug candidates through clinical trials and bring approved therapies to market.

The company’s flagship marketed product is Raxone (idebenone), a synthetic analogue of coenzyme Q10 that received marketing authorization in Europe for the treatment of visual impairment in patients with Leber’s hereditary optic neuropathy (LHON).